Adamas Pharmaceuticals Inc | Business Contracts

Agreement and Plan of Merger, dated as of October 10, 2021, by and among Supernus, Supernus Reef, Inc. and Adamas Pharmaceuticals, Inc (Filed With SEC on October 12, 2021)

First Amendment to Asset Purchase Agreement by and between Adamas Pharmaceuticals, Inc. and Osmotica Pharmaceutical US LLC (Filed With SEC on August 9, 2021)

Form of Performance Restricted Stock Unit Grant Notice and Award Agreement (Filed With SEC on May 10, 2021)

Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on February 23, 2021)

First Amendment to Amended and Restated Commercial Supply Agreement by and between Adamas Pharmaceuticals, Inc. and Catalent Pharma Solutions, LLC (Filed With SEC on August 8, 2019)

Binding Term Sheet by and between Adamas Pharma, LLC and Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc (Filed With SEC on May 10, 2021)

Underwriting Agreement, dated February 24, 2021, by and between the Company and SVB Leerink LLC and William Blair & Company, L.L.C., as representatives of the underwriters named... (Filed With SEC on February 25, 2021)

Amendment No. 3 to the Loan Agreement dated December 1, 2020 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 23, 2021)

Compensation arrangements with Executive Officers (Filed With SEC on February 23, 2021)

Adamas Pharmaceuticals, Inc. Amended and Restated Executive Severance Plan (Filed With SEC on February 23, 2021)

Asset Purchase Agreement by and between Adamas Pharmaceuticals, Inc. and Osmotica Pharmaceutical US LLC (Filed With SEC on February 23, 2021)

Extension to Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Rajiv Patni, dated July 15, 2020 (Filed With SEC on November 5, 2020)

Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on November 5, 2020)

2020 Compensation actions with respect to Non-Employee Directors (Filed With SEC on May 7, 2020)

Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Rajiv Patni, dated February 25, 2020 (Filed With SEC on May 7, 2020)

Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Jennifer Rhodes, dated January 9, 2020 (Filed With SEC on May 7, 2020)

Binding Term Sheet by and between Adamas Pharma, LLC and Sandoz, Inc (Filed With SEC on February 25, 2020)

Amendment No. 2 to the Loan Agreement dated January 2, 2020 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 25, 2020)

Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on February 25, 2020)

Description of Capital Stock (Filed With SEC on February 25, 2020)

Employment Offer by and between Adamas Pharmaceuticals, Inc. and Neil F. McFarlane, dated September 12, 2019 (Filed With SEC on November 7, 2019)

Transition, separation, and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Gregory T. Went, Ph.D., dated September 11, 2019 (Filed With SEC on November 7, 2019)

Separation and consulting agreement by and between Adamas Pharmaceuticals, Inc. and Alfred G. Merriweather, dated August 7, 2019 (Filed With SEC on November 7, 2019)

Offer Letter by and between Adamas Pharmaceuticals, Inc. and Vijay Shreedhar, Ph.D., dated May 14, 2019 (Filed With SEC on August 8, 2019)

Adamas Pharmaceuticals, Inc. Amended and Restated 2016 Inducement Plan (Filed With SEC on March 4, 2019)

Adamas Pharmaceuticals Inc (25)